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Tuberculous meningitis (TBM) is the most frequent and devasta­
ting form of central nervous system tuberculosis, resulting in 
considerable morbidity and mortality despite advances in anti­
tuberculosis agents.[1,2] The outcome depends on the stage of disease 
when treatment is commenced, with mortality of 15 ­ 50% in HIV­
negative patients and 25 ­ 80% in those who are HIV­infected.[3]
Other reasons for the poor prognosis include delayed diagnosis due 
to the nonspecific early symptoms, poor sensitivities of diagnostic 
tests, challenges regarding the current therapeutic regimens, and the 
host response to the infection. These problems have been highlighted 
in recent publications.[4,5]
There is little evidence to guide optimal treatment in TBM,[6] 
with the current choice of drugs, their dosages and the duration of 
treatment based on pulmonary tuberculosis (PTB) treatment.
Current South African (SA) and World Health Organization 
tuberculosis guidelines recommend 9 months’ treatment for TBM, 
consisting of intensive­phase therapy for 2 months with a combination 
of rifampicin, isoniazid, ethambutol and pyrazinamide, followed by 
7 months of rifampicin and isoniazid as first­line treatment.[7] Apart 
from a few studies[8,9] using 3 months, the duration of the intensive 
phase of treatment is 2 months. The total duration of antituberculosis 
therapy (ATT) in TBM varies from 9 to 18 months.
We have not infrequently seen patients improve during the 
intensive phase of treatment only to relapse once switched over to the 
continuation phase (unpublished observations). A patient recently 
admitted to our unit highlights this issue.
Case report
A 25­year­old HIV­negative woman presented to a regional 
hospital with a 1­month history of headaches, nausea, photophobia, 
phonophobia and associated night sweats. She was confused, with 
meningism and no focal neurological deficits. The disease severity 
at this point was classified as modified Medical Research Council 
(MRC) grade 1.[3]
The initial cerebrospinal fluid (CSF) examination revealed CSF 
glucose 1.6 mmol/L and protein 2.31 g/L, with 27 cells/µL (3 poly­
morphonuclear cells and 24 lymphocytes), Xpert MTB/RIF Ultra 
(Cepheid, USA) was positive with positive sensitivity to rifampicin. 
The cryptococcal antigen was negative. The patient was commenced 
on intensive­phase ATT without steroids. She reported symptomatic 
improvement, and at 8 weeks she was changed to continuation­phase 
ATT (rifampicin and isoniazid).
One week later, while she was on continuation­phase therapy, 
she presented with worsening severe headaches with vomiting. She 
also reported painful feet, with weakness in the lower limbs and 
lower back pain. Vision, swallowing and hearing were normal and 
the sphincters were reported as intact. She was transferred to the 
neurology unit at Inkosi Albert Luthuli Central Hospital, Durban, for 
further management.
On examination she was alert and co­operative with unremarkable 
findings on general examination. Neurological assessment revealed 
neck stiffness with a normal mental state. She had bilateral esotropia 
on primary gaze, with bilateral abduction deficits. The pupils were 
equal and reactive to direct light, and fundoscopy was normal. She 
had a flaccid quadriparesis with distal more than proximal weakness 
and was not ambulant. She had a thoracic level (T3) sensory level to 
all modalities. Disease severity was now classified as modified MRC 
grade 2. [3]
A chest radiograph was normal. Magnetic resonance imaging 
(MRI) of the brain (Figs 1, 2 and 3) revealed a focal area of white­
matter hyperintensity in the left temporal region and dilated occipital 
horns of lateral ventricles on a T2­weighted axial study. Post­contrast 
brain imaging showed features of diffuse leptomeningeal and basal 
meningeal enhancement with multiple punctate enhancing lesions 
involving the cerebral hemispheres and cerebellum. MRI of the spine 
(Fig. 4) showed extensive meningeal enhancement with enhancing 
lesions in the brainstem.
Repeat CSF examination revealed a protein level of 7.16 g/L, CSF 
glucose 4.7 mmol/L (plasma glucose 5.7 mmol/L), and 868 cells/µL 
(100 polymorphonuclear cells, 608 lymphocytes, 160 erythrocytes). 
The CSF was yellow in colour and Xpert Ultra was negative. HIV 
enzyme­linked immunosorbent assay was negative.
The patient was recommenced on intensive­phase ATT. Oral 
prednisone was added and inpatient rehabilitation was commenced. 
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On review 2 months after re­initiation of intensive therapy (i.e. 
4 months from diagnosis), she had improved dramatically and was 
able to walk.
Discussion
The Tuberculous Meningitis International Research Consortium 
discussed knowledge gaps in antimicrobial therapy at a meeting 
in Lucknow, India, but no mention was made of the duration 
of the intensive phase of treatment.[4] Similarly, a recent review 
reported current ongoing therapeutic trials, none of which entailed 
re­examining the duration of the intensive phase of treatment.[5]
The three most important elements by which treatment response can 
be measured are early morbidity, mortality and relapse rates.[10] The 
ideal ATT must fulfil two key requirements: enhanced activity against 
Mycobacterium tuberculosis, plus ability to achieve an adequate CSF 
concentration.[11] In evaluating regimens for the management of 
PTB, relapse rates of 5% are often considered satisfactory; however, 
in the case of TBM it must be ascertained whether any risk of relapse 
is acceptable.[10] A study by Pusch et al.[12] reviewed the long­term 
mortality of extrapulmonary tuberculosis syndromes. They found 
that the therapy duration associated with lowest mortality for 
TBM was 8 months, and that thereafter mortality increased with 
longer duration of therapy. This was a small retrospective study and 
intensive­phase therapy durations were not specified.
Furthermore, the current ATT regimen is based largely on expert 
opinion and does not take into account the differential ability of 
antituberculosis drugs to penetrate the blood­brain barrier (BBB) or 
blood­cerebrospinal fluid barrier, potentially resulting in suboptimal 
CSF concentration, disease site exposures, bacterial killing and 
treatment outcomes.[13]
Isoniazid and pyrazinamide have good CSF penetration, with CSF 
concentrations of 80 ­ 90% and 90 ­ 100%, respectively, and display 
treatment­shortening ability.[11] Isoniazid has early bactericidal 
activity and is metabolised by polymorphic N­acetyltransferase 2 with 
two phenotypic patterns: fast and slow metaboliser. Slow acetylators 
have been noted to have high plasma and CSF concentrations.[13] CSF 
penetration of total rifampicin is poor and penetration of ethambutol 
is the poorest, with CSF concentrations of 10 ­ 20% and 20 ­ 30%, 
respectively, even with an inflamed BBB.[11]
Rifampicin at a dose of 450 ­ 750 mg/d appears to be well tolerated, 
with ~3% of adverse reactions reported to require discontinuation, 
even when combined with isoniazid. The incidence of clinical 
hepatitis ranges from 2% to 11% of patients treated with rifampicin, 
isoniazid and pyrazinamide, which appears to be idiosyncratic 
but could be dose related in the presence of pre­existing liver 
disease. [14,15] Prolonged use of intensive­phase ATT requires caution, 
especially in patients with risk factors predisposing to possible 
adverse events.
Fig. 1. T2-weighted axial image showing focal area of white-matter hyper-
intensity in the left temporal region (arrow) and dilated occipital horns of 
lateral ventricles (arrowhead).
Fig. 2. Features of diffuse leptomeningeal enhancement marked in the left 
temporal region (arrow).
Fig. 3. Basal meningeal enhancement (arrow) with multiple punctate 
enhancing lesions diffusely involving the cerebral hemispheres and 
cerebellum (arrowhead). 
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Early aggressive ATT results in early 
improvement and is based on the antici­
pation that incomplete treatment may lead 
to increased rates of death, relapse and 
neurological sequelae.[16] On the other hand, 
prolonged treatment adds to the adverse 
effects of medications and can lead to poorer 
compliance.
The intensive phase of treatment may 
be a potential point of intervention for 
improving outcome. A number of studies 
have studied or are studying different 
drug regimens for the intensive phase of 
treatment.
Various clinical trials have investigated 
hyper­intense ATT with either intravenous 
rifampicin or a higher dose of oral rifampicin 
with addition of fluoroquinolones during 
the intensive­phase therapy. These studies 
showed no effect on clinical outcome or 
improvement in survival compared with 
standard therapy. In contrast, isoniazid 
exposure was associated with improved 
survival, while low exposure was predictive 
of death and was linked to the fast­
metaboliser phenotype.[13] Higher doses of 
isoniazid should be investigated, especially 
in fast metabolisers.[1,10,11,13,17­19] In one 
randomised controlled trial, standard­dose 
levofloxacin was compared with standard­
dose rifampicin, together with isoniazid, 
pyrazinamide and ethambutol. Patients 
receiving levofloxacin had improved 
outcomes, possibly due to better CSF 
penetration of levofloxacin compared with 
rifampicin.[20]
Linezolid is well established for the 
treatment of PTB and has an additive 
effect when combined with rifampicin. 
A  retrospective study in adults with TBM 
suggested a favourable outcome.[21] Agents 
such as the nitroimidazole, delamanid, may 
be another reasonable option.[22]
Going forward, the options of mani­
pulating the intensive phase of treatment 
include evaluating drug penetration into the 
CSF, increasing the duration of intensive­
phase treatment using the standard agents, 
and combining the standard drugs with 
other drugs. Possible variations in the 
management of the intensive phase are 
summarised in Table 1.
Our patient was not commenced on 
cortico steroid therapy at the regional hospi­
tal at the time of diagnosis of TBM. Despite 
this, there was a marked improvement in 
her symptoms. Deterioration was noted 
after the change to continuation­phase 
therapy. Because the clinical deterioration 
occurred after this change, it was not 
attributed to a paradoxical reaction. This 
conclusion is further supported by her 
continued clinical improvement while 
on intensive­phase treatment and relapse 
within a week of introduction of the 
continuation­phase therapy. Her dramatic 
clinical improvement when re­initiated on 
intensive­phase therapy is further evidence 
against a possible paradoxical reaction.
Conclusions
Meningitis is the most devastating mani­
festation of tuberculosis, with high 
morbidity and mortality. The duration of 
the intensive phase of treatment of TBM 
has been extrapolated from data obtained 
in the management of PTB. The optimal 
antimicrobial intensive treatment regimen 
for TBM has not been established in clinical 
trials. Little attention has been paid to this 
aspect of treatment.
The patient under discussion highlights 
the shortcomings of the current treatment 
guidelines. In our view, the duration of 
the intensive phase of therapy is too short. 
Research should be directed towards 
evaluating a longer duration of intensive­
phase therapy with the standard drugs or 
with combinations of different drugs in 
randomised controlled studies addressing 
the deficiencies of current regimens.
In the interim, we suggest using intensive­
phase treatment (rifampicin, isoniazid, pyra­
zinamide and ethambutol) for a minimum 
of 3 months.
A B
Fig. 4, A and B. Extensive meningeal enhancement (arrows) with enhancing lesions in the brainstem 
(arrowhead).
Table 1. Possible changes in the intensive phase of therapy: Potential regimens
1. Commence RHZE for 3 months, then continue with RH for 6 ­ 9 months[9]
2. RHZE for 2 months, then RHZ as the continuation phase
3. Start with RHZEth for 2 or 3 months, then RH 
4. High­dose R in various formulations and combinations with the other standard agents for 3 months, then standard continuation phase[9]
5. Levofloxacin with HZE for 2 months, then continue with HZ
6. Commence RHZE with high­dose H – fast acetylator[13]
7. RHZ + linezolid for 2 ­ 3 months, then continue with RH
8. Delamanid in the future?
R = rifampicin; H = isoniazid; Z = pyrazinamide; E = ethambutol; Eth = ethionamide; L = levofloxacin.
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